A Study of YL202 in Patients With Advanced Solid Tumors
Trial Parameters
Brief Summary
This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in selected patients with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria: * Subjects must meet all the following criteria to be included in the study: 1. Subjects who are aware of relevant study information prior to the start of the study, and voluntarily sign and date on the informed consent form (ICF). 2. Subjects aged ≥18 years at the time of giving informed consent 3. Body mass index (BMI) within the range of 18 to 32 kg/m2. 4. Subjects with histologically or cytologically confirmed non-Sq NSCLC/CRC/CC or other advanced solid tumor, and had received 1-2 lines of systemic therapy in the advanced/metastatic setting 5. There is at least one extracranial measurable lesion as the target lesion per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. 6. Archived or fresh tumor tissue samples are available. 7. Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1. 8. The function of organs and bone marrow meets the requirements within 7 days prior to the first dose 9. Female subjects of childbearing poten